allergy indications - Heel BHI

allergy indications
Addressing your patients needs safely and effectively

inTroducTion
Allergies pose major health problems. Not only does
disease-like allergic rhinitis affect 20 to 40 million people
annually, it also results in an accumulative 3.8 million
lost work and school days. The wide coverage of anti-
allergic medicine in the media and on supermarket shelves
also alludes to the widespread impact of this condition.
The allergic response
Allergy represents an inappropriate reaction of an organism to a mostly innocuous
substance. Allergens could be seasonal, such as mold, grasses, trees and pollens, as
well as perennial (through the year), such as dust mites and animal dander. Irritants, like
cigarette smoke and diesel exhaust fumes may promote the allergic response, but are not
allergens in themselves. It is important to note that for the immune system to develop an
allergic response, the substance needs to possess a peptide sequence or an amino acid
sequence.
Why is the immune system so vulnerable today?
As with the development of all diseases, the development of allergies depends on three
factors: genetic predisposition, environmental influences and a trigger.
The genetic predisposition has been well studied in patients with allergies. Experiments
conducted in the 1920’s already showed that if two parents were allergic, 50% of their
offspring would be allergic, and even if one parent was allergic, 30% of thier offspring
stood a chance to be allergic.
The effects of environmental toxins have been mentioned, but it is also important to note
that allergic mediators, such as histamine, are internal toxins and are cleared from the
system through liver detoxification. If the liver is overloaded, or missing certain important
co-factors, the patient will not be able to remove the histamine from the system, and
will have more symptoms of allergy. If certain immunotoxic chemicals are not cleared
from the body, and are stored in the matrix, they can contribute to an abnormal immune
response. Detoxification and support of the detoxifying organs is an integral part of the
homotoxicological approach to allergy.
The cytokine environment in the tissues is also of special importance. It is well recognized
now that patients with allergies have an immune response which, on a cellular level, is
skewed towards a certain reaction, namely a TH2 response.
Normally, T-helper cells circulate as T-0 cells, and depending on which antigen it is
presented with (via the antigen presenting cells such as macrophages and dendritic cells)
it will develop into a TH1 cell, TH2 or a TH3 cell (Figure 2).
Fig. 1: The allergic response.
Dust Mite
The incidence of allergy is increasing and numerous factors have been postulated for
this. People living in urban areas are more prone to allergic disease. Environmental
factors, such as diesel exhaust fumes, and especially sulfur dioxide, as well as
ozone and overcrowding have all been implicated in allergic disease. Environmental
toxins like sulfur dioxide not only predispose the immune system to allergy, but also
change the quality of the nasal mucosa so that it has a hyper-responsiveness towards
allergens. It may also change the structure of an antigen-like pollen so that it becomes
more allergenic.
These cells secrete different
messengers called cytokines,
which will then generate the
appropriate immune response.
In the case of a virus or fungal
infection, a TH1 response is
preferred. TH1 will generate a
cellular immune response via the
secretion of the cytokines IFN
gamma, Tumor Necrosis Factor
IL-2
IFN gamma
TNF
Inflammation
DHEA
TGF-ß
Inhibition
Cortisol
IL-4, 13
IL-5
IL-10
Allergy
(TNF), and IL-1 to kill these invaders. Antibodies are made when TH2 cells are stimulated,
as TH2 cells will activate plasma cells. The TH2 cells secrete other cytokins Interleukin 4, 5,
10, and 13, apart from other cytokins. These cytokines are closely involved in the allergic
response, as Interleukin 4 and 13 induce IgE formation, Interleukin 5 enhances the growth
of eosinophils and Interleukin 10 promotes mast cell growth (See also the Immunology of
Allergy).
TH3 helper cells are regulatory T-cells and secrete mainly a cytokine called Transforming
Growth Factor beta (TGF-ß), which is an anti-inflammatory that facilitates tissue repair, and
may be able to restore the balance between TH1 and TH2.
In healthy individuals there is a small daily oscillation between TH1 and TH2 cells, so that
the body is always ready to respond in a certain fashion. It is a well known fact that allergic
patients are slanted towards a TH2 response. Some patients are born with this skewed
response, especially if they are allergic from birth. This means that the immune system
will easily go down the TH2 pathway in response to antigens, and cause allergic reactions
more easily.
Fig. 2: TH1/TH2 balance.
In Homotoxicology, we call this skewed response “regulation rigidity” and we should
endeavor to restore the normal physiological oscillations between TH1 and TH2 cells.
Traumeel has been shown to down regulate the pro-inflammatory cytokines, and to
increase TGF-ß, and it is postulated to induce TH3 cells.

Infections with parasites and fungi can also promote the TH2 response. These organisms
are mostly eliminated via a TH1 response, but they have developed a mechanism to escape
this by pushing the immune system into the TH2 state via some of the surface proteins, like
mannan, in the case of fungi. Allergy is often a concomitant finding in these diseases.
The hygiene hypothesis is of particular interest, where it is postulated that the modern use
of vaccines and antibiotics to ban banal disease (which mostly will mount a TH1 response),
results in a skewed immune response towards the allergic (TH2) side.
In Homotoxicology, we recognize both the effects of toxins on the organism (in this
case the immune system), as well as the dangers of suppressing banal disease in the
development of chronic disease and regulation rigidity. The Homotoxicological approach
to allergy will focus on three points:
• Drainage and detoxification
• Treatment of the regulation rigidity of the immune system
• Treatment of the symptoms of allergic disease.
These three points cause the most distress in patients.
The allergic response itself is depicted in the diagram below (Figure 1), and consists of
three phases: Phase I: sensitization or priming, Phase II: the Early Allergic Response (EAR),
and Phase III: the Late Allergic Response (LAR).
Allergy is never seen on the first exposure to an antigen, because the allergic response
is a type-I (anaphylactic) response which is mediated by IgE antibodies, and cells such
as macrophages, mast cells, T-helper cells (especially TH2 cells), and eosinophils. The
first sensitization occur and that the mast cell gets primed with IgE, which is specific for
that allergen.
The immunology of The allergic response
1. sensitization:
It may take up to 4 years for the primed mast cells to reach a critical mass for a specific
antigen in a region in order to illicit an allergic response to that antigen. It is important to note
that an allergic response may also occur without apparent previous exposure to an antigen,
such as penicillin. This is due to cross allergies. The priming or sensitization of the immune
system may have taken place via mold in the environment, which has an antigenic similarity
to penicillin, and upon exposure to penicillin (a mold) for the first time, the patient may then
get an allergic reaction. Cross allergies also exist between food and environmental allergens.
For instance, grass pollens cross-react with
tomatoes, and seeds of legumes such as
peas and beans, and grains while natural
latex cross reacts with bananas, avocados
and grains. Therefore, a patient eating a lot
of bananas may suddenly develop an allergy
to latex gloves.
2. The early allergic response (ear)
This takes place in the first 2-20 minutes after re-exposure to the antigen and in the
presence of enough mast cells primed with IgE to react to that specific antigen. The
mediators, such as histamine, increase vascular permeability and an influx of fluid.
Leukotrines and prostaglandins cause inflammation. Chemo attractants are responsible for
the recruitment of other immune cells, like basophils. The clinical result is itching, sneezing
and bronchospasm.
3. The late allergic response (lar)
The Late Allergic Response is mediated via the cytokines from the products of the mast
cells and TH2 cells, this develops in 4-10 hours after re-exposure. LAR involves the
attraction of immune cells and also the maturation of the aforementioned cells. IL5 (from
the mast cell and TH2 cell) can induce the growth of eosinophils, which are the main cells
associated with the Late Allergic Response.
The eosinophils de-granulate and secrete a number of substances, notably major basic
protein and other substances like eosinophil derived neurotoxin, and peroxides. This will
cause tremendous inflammation, which is the key characteristic of chronic allergy. The Late
Allergic Response is responsible for the severity of asthma and is the component that is
treated by corticosteroids. It is also the hallmark of diseases such as Chronic Eosinophilic
Allergic Sinusitis where the response to a fungus is that of an eosinophilic infiltration,
which eventually will give rise to destruction of the mucosa via the major basic protein
(Figure 1).
homoToxicology and allergy
According to the theory of Homotoxicology, disease follows the body’s inability
to maintain homeostasis by regulation in the face of a toxin or other aggressor.
In this case, the internal toxin is histamine and the dysregulation is the skewed
immune response.
The actions of histamine upon various tissues can be followed quite well in the body, and
offer one of the best examples of a phenomenon called vicariation. Histamine in its different
isoforms is active in various tissues like the skin, the mucosal membranes of the nose
and lung, as well as in the gastric mucosa, the brain, and even the heart. It is involved in
allergic rhinitis in the nose, asthma in the lung, eczema on the skin, ulceration in the gastric
mucosa and also plays a part in myocardial infarction.
Reckeweg postulated from the work of Constantine Hering and others, that if the normal
regulatory mechanisms are suppressed or not successful, toxins such as histamine will
cause disease in the body from the outside, inward, or from superficial embryological
tissues to deeper ones. This is depicted on the Six-Phase Table of Homotocicology and is
called progressive vicariation if it goes deeper and to the right on the table, and regressive
vicariation if it moves toward more superficial tissues and the left of the table.

If superficial eczema is suppressed by topical cortisone, it
may shift to a deeper tissue such as the lungs, and asthma
may occur. It is well known in practice that in patients
where both co-exist, the eczema gets worse when the
asthma gets better, or reversed. In a patient with asthma,
the development of eczema is seen as a regressive
vicariation, and is welcomed rather than suppressed.
Suppression will result in progressive vicariation to
deeper tissues and into phases towards the right of the biological division, such as the
impregnation phase (asthma). Suppression of disease on the skin may also vicariate
to other tissues like the gastric mucosa and may lead to development of gastritis or
ulcers as well. In Homotoxicology, an attempt is always made to regulate (get the body
to balance physiologically), rather than to suppress the symptom.
The homotoxicological approach is depicted in Figures 4 and 7 and employs the three
pronged approach of symptomatic support, not suppression. Treating the allergic terrain
is achieved by supporting the detoxifying organs, especially the liver and the matrix, as
well as immune-regulation (via the down-regulation of inflammatory mediators) and the
induction of TH3 regulatory cells.
The symptomatic treatment is different for the different allergic diseases, but the
detoxification and the regulation of the allergic response is the same.
eczema:
Eczema is a difficult condition to treat and is often treated with topical steroids
which, from a homotoxicological perspective, may result in deeper disease such
as asthma (Figure 5).
Eczema may present with a wide variety of clinical pictures, and according to the drug
pictures of the various homeopathic constituents in the homotoxicological remedies,
one can choose a specific product for each type (Figure 6-7). The liver and skin has
a special relationship as they have the same detoxification mechanisms. Histamine is
broken down by the P450 system active in both tissues, and if the liver is overloaded,
the histamine can be active in the skin as well. Liver drainage is very important in all
skin diseases.
allergic rhinitis:
This debilitating condition can be treated by biological medicine, and typically, the
patient is less allergic every new season, i.e. each allergic season is better than
the previous one, even if one treats only during the allergy season. The regulatory
treatment will have a longer and accumulative effect. In seasonal allergies,
treatment should be started at least six weeks before onset of the allergy season.
asthma:
The six-phase Table - allergies and applicaTion of Therapy (abridged)
Bronchial asthma has become the most common cause for hospitalization of children in
the United States. In regards to asthma, treatment should be aimed at all three components
leading to the obstruction in the airways: bronchospasm, mucous plugs and inflammation
(Figure 7). In Homotoxicology, Tartephedreel ® and Engystol ® are aimed at the bronchospasm,
while Traumeel treats the inflammation. Bronchalis-Heel ® treats the mucous plugs and can
be left out if the patient does not have a lot of sticky phlegm. In conventional treatment,
the bronchodilators will treat the bronchospasm, but the corticosteroid will treat the late
response (inflammation). This is why cortisone will not give immediate relief in asthma, but
a bronchodilator will. This is also the reason to wean a patient off the bronchodilator first.
Weaning of patients off conventional therapy is a slow process and may take up to a year.
Weaning should only be attempted after the simultaneous treatment with the conventional
and the Homotoxicological therapy continues for awhile, as some regulation must be
possible before the conventional support is withdrawn. A possible schedule is proposed in
Figure 3, but it is important to note that the response may differ from patient to patient. The
clinical picture, as well as the peak expiratory flow rate, must be monitored closely, and the
treatment adjusted. The patient may need to stay on conventional treatment longer.
H u m o r a l P H a s e s m at r i x P H a s e s C e l l u l a r P H a s e s
organ system excretion phases inflammation phases deposition phases impregnation phases degeneration phases dedifferentiation phases
Tissue damage No enzyme damage; Excretion principle; Natural healing tendency Enzyme damage; Compensation principle; Chronic Diseases
skin Episodes of sweating Acute eczema Naevi Allergy, chronic eczema,
urticaria
Scleroderma Melanoma
respiratory
Tract
gastrointestinal
system
Cough, expectoration Bronchitis, acute sinusitis Nasal polyps Asthma, allergic rhinitis Bronchiectasia, emphysema,
eosinophilic rhinitis
Heartburn Gastroenteritis, gastritis Hyperplastic gastritis Food allergy Atrophic gastritis, liver
cirrhosis
blood Reticulocytosis Leucocytosis, suppuration Polycythaemia,
thrombocytosis
lymph system Lymphedema Lymphangitis, tonsillitis,
lymphadenitis
immune system Susceptibility to infection Weak immune system,
acute infection
Weeks 1-12 Weeks 12-18 Weeks 18-24 Weeks 24-30 Weeks 30-36 Weeks 36-42
homotoxicology Symptomatic + Symptomatic Symptomatic + Symptomatic Symptomatic + Symptomatic
Regulation
Regulation
Regulation
steroid Full dose Full dose Full dose Half dose Try to stop/ Try to stop/
half dose half dose
long acting
bronchodilator
Full dose Half dose Stop
short acting At hand for At hand for At hand for At hand for At hand for At hand for
bronchodilator acute need acute need acute need acute need acute need acute need
Fig. 3: Proposed schedule for the weaning of conventional medicine in asthma patients.
Symptomatic
treatment
• Eczema
• Asthma
• Allergic Rhinitis
• Allergic Conjunctivitis
Lymph-node swelling Insufficiency of the lymph
system
Weak reactions Autoimmune disease,
immunodeficiency, chronic
infections
Aggregation disturbance Anemia, thrombocytopenia Leukemia
Bronchial carcinoma
Stomach cancer, colon
cancer
Fibrosis Lymphoma, Hodgkin-/ non-
Hodgkin-lymphoma
AIDS Slow reactions
The six-phase table is a field matrix reflecting medical experience based on careful observation and empirical learning. It is a phase-by-phase arrangement of disorders with no direct relationship between them. No causal pathogenetic link between disorders
can be inferred. The structure of the table makes it suitable for developing a prediction system giving a better assessment of the possibilities for a vicariation effect. © 2000 by Biologische Heilmittel Heel GmbH.
biological division
Allergy
Treating the
allergic terrain
Detoxification
and drainage •
Immunomodulation •
Stimulating tissue
metabolism •
Fig. 4: Homotoxicological approach to allergy.

egulaTory TreaTmenT
Drainage:
liver
Hepeel
Hepar compositum ®
matrix:
Galium-Heel
Pulsatilla compositum
Thyreoidea compositum ® (Rx)
Lymphomyosot ®
Fig. 5: Eczema cross-section.
Treating the allergic terrain:
immunomodulation
Traumeel ®
Cutis compositum ®
Mucosa compositum ®
Tissue metabolism (catalyst)
Coenzyme compositum
Ubichinon compositum ®
Glyoxal compositum ®
sympTomaTic TreaTmenT
Fig. 6: Symptomatic treatment of eczema.
product Type of eczema
Graphites Homaccord Weepy eczema with honey
colored discharge and
crusting. Also eczema around
ears and head.
Sulphur-Heel Mixed types, vesicular, itchy,
but with dry patches.
Schwef-Heel Dry, intensively itchy, worse
in heat.
Lamioflur Intractable, often around the
body orifices.
Abropernol ® Dry, itchy, in the folds.
Mezereum Homaccord Vesicular eczema with a
tendency towards pustule
formation.
asthma
Bronchalis-Heel •
Tartephedreel •
Engystol ® •
Traumeel ® •
allergic conjunctivitis •
Oculoheel ®
BHI Hayfever (Luffeel ® )
allergic rhinitis •
BHI Hayfever (Luffeel ® )
Euphorbium Sinus Relief
Naso-Heel
Fig. 7: Allergic Rhinitis, Conjunctivitis, and Asthma.

proTocols
Table 1: Allergic Rhinitis and Conjunctivitis
symptoms BHI Hayfever (Luffeel ® ),
Oculoheel
injecTion Therapy
For the treatment of:
Eczema
Technique:
Injection into point
(Homeosiniatry)
Remedies:
Traumeel ®
Lymphomyosot ®
Points:
DU 14
LI 11
SP 6
SP 10
ST 36
H 7
LI 11 •
LI 4 •
For the treatment of:
Allergic rhinitis
Technique:
Injection into point
(Homeosiniatry)
Remedies:
Traumeel ®
Lymphomyosot ®
Points:
LI 4
LI 20
L 7
ST 36
SP 6
GB 20
mild to moderate moderate to severe
ST 36 •
ST 40 •
BHI Hayfever (Luffeel ® ), Naso-Heel
(anosmia), Euphorbium Sinus Relief
(polyps), Oculoheel
Hepar compositum ® , Lymphomyosot ® ,
Pulsatilla compositum
drainage
Allergic terrain
Hepeel, Galium-Heel,
Lymphomyosot
immunomodulation Traumeel ® ,
Mucosa compositum ®
catalysts Coenzyme compositum Coenzyme compositum,
Ubichinon compositum ®
Traumeel ® , Mucosa compositum ®
• Yin Tang
• LI 20
• CV 22
• CV 21
• SP 10
• SP 6
• CV 17
• CV 4
© 2005 Heel Inc. Heel, BHI, Homaccord, Abropernol, Cutis compositum, Engystol, Glyoxal compositum, Hepar compositum, Husteel, Lymphomyosot, Mezereum Homaccord,
Mucosa compositum, Thyreoidea compositum, Traumeel, and Ubichinon compositum are all registered trademarks of Biologische Heilmittel Heel GmbH. No portion of this publication
may be reproduced without written authorized permission. The contents of this brochure are for educational, informational, and product description purposes only. In no
event shall Heel Inc. be liable for any special, indirect or consequential damages or any damages whatsoever resulting from the use of any information contained within. Heel Inc.
assumes no responsibility for errors or omissions in any information provided in this brochure, nor does it warrant the accuracy or completeness of the information, text, graphics,
or other items contained within these materials.
• L 7
• H 7
Table 2: Asthma
mild to moderate moderate to severe
symptoms Tartephedreel, Husteel ® , Tartephedreel, Husteel
Bronchalis-Heel
® ,
Bronchalis-Heel
drainage Hepeel, Pulsatilla compositum,
Lymphomyosot ®
Hepar compositum, Lymphomyosot ® ,
Thyreoidea compositum ® (Rx)
immunomodulation Traumeel, Engystol
Mucosa compositum ®
Traumeel, Engystol, Mucosa compositum,
Tonsilla compositum
catalyst Coenzyme compositum,
Ubichinon compositum ®
Coenzyme compositum,
Ubichinon compositum ®
Intersperse with Glyoxal compositum ®
Table 3: Eczema
mild to moderate moderate to severe
symptoms See Figure 6 on page 4 for
specific type
See table on page 4 for specific type
drainage Hepeel, Galium-Heel,
Lymphomyosot ® Hepar compositum
, Pulsatilla
compositum (After cortisone)
® , Pulsatilla
compositum, Thyreoidea compositum ® (Rx),
Lymphomyosot ®
immunomodulation Traumeel ® , Cutis
Traumeel ® , Cutis compositum ®
compositum ®
catalyst Coenzyme compositum Coenzyme compositum,
Ubichinon compositum ®
C 7 •
T 6 •
Injection Technique:
Injection into point (Homeosiniatry) should be 0.1ml
each remedy with a half-inch, 30 gauge needle.
3110010/1205/12000
• GB 20
• DU 14
For the treatment of:
Asthma
Technique:
Injection into point
(Homeosiniatry)
• BL 13
Remedies:
Traumeel ®
Zeel ®
Points:
CV 4
CV 17
CV 21
CV 22
ST 36
ST 40
BL 13
LI 4
DU 14
Heel Inc.
Albuquerque, NM
p: 1-800-621-7644
f: 1-800-217-6934
www.heelusa.com